Skip to content
Cemdisiran
Cemdisiran is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C10: Lipid modifying agents
C10A: Lipid modifying agents, plain
C10AX: Other lipid modifying agents in atc
C10AX16: Inclisiran
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Paroxysmal hemoglobinuriaD006457Orphanet_447D59.12235
Myasthenia gravisD009157EFO_0004991G70.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atypical hemolytic uremic syndromeD06576622
Iga glomerulonephritisD005922EFO_000419411
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEMDISIRAN
INNcemdisiran
Description
Cemdisiran is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Classification
Oligonucleotide
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID1436858-07-9
RxCUI
ChEMBL IDCHEMBL4297722
ChEBI ID
PubChem CID
DrugBank
UNII IDS66Z65E10T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 75 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details